Reports from a retrospective review of source documents associated with a patient assistance program ((b) (6)  
(b) (6) ).
AER 1330716, is a non interventional program case, received on 20/Jul/2011 from a rheumatologist and concerns 
a female patient (patient id (b) (6) ) of unspecified age who developed progressive multifocal leucoencephalopathy 
while participated (b) (6)
Patient's medical history included drug allergy to propoxyphene, meperidine, levofloxacin. No concurrent illnesses 
were reported. Concomitant medications include prednisone. Past medications included abatacept, levofloxacin, 
infliximab, pethidine hydrochloride, methotrexate, certolizumab pegol, dextropropoxyphene.
On an unspecified date, the patient started rituximab (therapy details not provided) for rheumatoid arthritis. Later, 
Print Time: 24-MAY-2016 07:56 AM If a field is blank, there is no data for that field Page 167 of 570
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
on she developed progressive multifocal leukoencephalopathy and she was prescribed with tocilizumab (therapy 
had not started). 
At the time of this report, the outcome of progressive multifocal leukoencephalopathy was not reported and it was 
not known whether the therapy with rituximab was ongoing or not.
The rheumatologist did not provide the causal relationship between progressive multifocal leukoencephalopathy 
with rituximab.
The company assessed the progressive multifocal leukoencephalopathy as medically significant.
No further information was provided.